NASDAQ · VINCW
Vincerx Pharma, Inc.
Healthcare · Biotechnology
$1.61
Down-$0.42 (-20.69%)
Updated Aug 15, 2026, 5:51 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 28.01M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 25.44K
- Avg. volume
- 0
Price performance
VINCW price history
1M range · 0 trading sessions · Daily adjusted prices
VINCW does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest VINCW news
The latest Smart Investors Daily articles mentioning VINCW.
Stock researchCompany · Overview
VINCW research
Overview
Company profile and research snapshot.
Company profile
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 6, 2021 | Chardan Capital | Buy | — |
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
